Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically documented primary brain tumor for which surgical resection is indicated.~* Age 18 years and older.~* ECOG Performance status less than or equal to 2.~* Laboratory values as follows:~Leukocytes greater than or equal to 3,000. ANC greater than or equal to 1,500. Platelets greater than or equal to 100,000. Total Bilirubin WNL. AST/ALT less than or equal to 2.5 times ULN. Creatinine WNL. or Creatinine Clearance greater than or equal to 60ml/min/1.73m2 if SCr above institutional normal.~-Ability to provide informed consent or consent from a Legally Authorized Representative.~Exclusion Criteria:~* Receipt of an investigational agent within 30 days.~* Allergy to ALA or similar compounds.~* Personal or family history of porphyria.~* Uncontrolled intercurrent illness.~* Inability to comply with the protocol.~* Pregnancy, breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aminolevulinic Acid (AL) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).